{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-067951","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.771758+00:00","generated_at":"2026-05-18T06:30:58.992361+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioXcel Therapeutics receives USPTO allowance for key IGALMI patent expiring 2043","bullets":["USPTO allowed U.S. Patent Application No. 18/600,419 for single-dose oromucosal dexmedetomidine up to 120 mcg.","Claims cover acute agitation treatment in schizophrenia or bipolar disorder with QT prolongation <6 microseconds.","Allowed claims mirror the recommended IGALMI dosing regime for that patient subpopulation.","This will be the 14th Orange Book-listed patent for IGALMI, expiring January 12, 2043 subject to adjustment.","CFO Richard Steinhart signed the 8-K filed July 15, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-067951","json":"https://secwatch.observer/filing/0001104659-25-067951.json","markdown":"https://secwatch.observer/filing/0001104659-25-067951.md","text":"https://secwatch.observer/filing/0001104659-25-067951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925067951/0001104659-25-067951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925067951/tm2520959d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-18T06:30:58.992361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}